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Abstract
Background: Inflammatory lung diseases are a major morbidity factor in children. Therefore, novel strategies for
early detection of inflammatory lung diseases are of high interest. Bacterial lipopolysaccharide (LPS) is recognized
via Toll-like receptors and CD14. CD14 exists as a soluble (sCD14) and membrane-associated (mCD14) protein,
present on the surface of leukocytes. Previous studies suggest sCD14 as potential marker for inflammatory diseases,
but their potential role in pediatric lung diseases remained elusive. Therefore, we examined the expression,
regulation and significance of sCD14 and mCD14 in pediatric lung diseases.
Methods: sCD14 levels were quantified in serum and bronchoalveolar lavage fluid (BALF) of children with infective
(pneumonia, cystic fibrosis, CF) and non-infective (asthma) inflammatory lung diseases and healthy control subjects
by ELISA. Membrane CD14 expression levels on monocytes in peripheral blood and on alveolar macrophages in
BALF were quantified by flow cytometry. In vitro studies were performed to investigate which factors regulate
sCD14 release and mCD14 expression.
Results: sCD14 serum levels were specifically increased in serum of children with pneumonia compared to CF,
asthma and control subjects. In vitro, CpG induced the release of sCD14 levels in a protease-independent manner,
whereas LPS-mediated mCD14 shedding was prevented by serine protease inhibition.
Conclusions: This study demonstrates for the first time the expression, regulation and clinical significance of
soluble and membrane CD14 receptors in pediatric inflammatory lung diseases and suggests sCD14 as potential
marker for pneumonia in children.
Introduction
Inflammatory lung diseases of infective or non-infective
origin are among the leading morbidity and mortality
factors in children and require early diagnosis for speci-
fic treatment to prevent disease progression and chronic
lung remodelling [1,2]. Therefore, novel strategies for
early detection of inflammatory and infective lung dis-
eases in childhood are of high interest.
Lipopolysaccharide (LPS) is recognized by the human
immune system via binding to LPS binding protein
(LBP) and transferrring the LPS/LBP complex to CD14
[3,4]. CD14 is a myeloid differentiation antigen that is
mainly produced by monocytes and macrophages. CD14
acts as a receptor for bacterial LPS in cooperation with
Toll-like receptor 4 (TLR4) [5]. The binding of LPS via
LBP and CD14 to TLR enhances mitogen activated pro-
tein kinase (MAPK) signalling and promotes the secre-
tion of pro-inflammatory cytokines and chemokines [6].
CD14 can bind bacterial ligands and receptors on pha-
gocytes, thereby mediating phagocytosis of bacteria and
clearance of apoptotic cells [3,7,8].
CD14 exists as a soluble (48/56 kDa) and membrane-
associated glycosylphosphatidylinositol (GPI)-anchored
(55 kDa) protein, present on the surface of monocytes,
macrophages, dendritic cells and neutrophils [4,8]. The
soluble form of CD14 (sCD14) is produced either by
proteolytic cleavage or by secretion without the GPI
moiety by monocytes [9,10]. Soluble CD14 is detectable * Correspondence: veronica.marcos@med.uni-muenchen.de
1Children’s Hospital of the Ludwig-Maximilians-University, Munich, Germany
Marcos et al. Respiratory Research 2010, 11:32
http://respiratory-research.com/content/11/1/32
© 2010 Marcos et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.both in serum and bronchoalveolar lavage fluid (BALF)
[11]. Recently, Dressing et al. demonstrated in a murine
model that Streptococcus pneumoniae utilizes sCD14 in
the bronchoalveolar space to cause invasive respiratory
tract infections [12]. When viewed in combination,
sCD14 is deemed to act as a key component in pulmon-
ary inflammation/infection and may represent a promis-
ing marker and therapeutic target in respiratory
diseases.
The expression, regulation and clinical significance of
sCD14 and mCD14 in pediatric lung diseases has not
been defined. Therefore, we quantified sCD14 and
mCD14 levels in peripheral blood and BALF of children
with infectious and non-infectious pediatric lung disease
and healthy control groups. Furthermore, we examined
which factors induce the release of sCD14 by peripheral
blood mononuclear cells (PBMCs) in vitro.
Methods
Study design
Soluble and membrane CD14 expression levels were
analyzed in serum and BALF of age-matched children
with pneumonia (n = 48 all pneumonia, n = 31 bacterial
pneumonia), cystic fibrosis (CF, n = 39); allergic asthma
(n = 15) and healthy control subjects (n = 8) (table 1).
The pneumonia group included 48 children with a
mean age of 11 ± 4 (SD) years. All pneumonia patients
were inpatients of the Children’s hospital of the Univer-
sity of Munich and underwent detailed diagnostic work-
up. BAL was initiated by the attending physician for
further diagnostic clarification, in particular since a large
proportion of the included patients had chronic pul-
monary symptoms. Pneumonia patients were stratified
in ‘bacterial pneumonia’ and ‘non-bacterial pneumonia’.
Bacterial pneumonia was diagnosed when the following
criteria were given (i) infiltrates in chest radiographs, (ii)
increased C-reactive protein (CRP), elevated white blood
cell count (WBC) and/or accelerated erythrocyte sedi-
mentation rate (ESR), (iii) clinical signs of pneumonia
(cough, dyspnoe, tachypnoe, fever) and (iv) detection of
bacterial pathogens in BALF. The bacterial pneumonia
group included 19 male and 12 female children. The CF
group included 23 male and 16 female patients with a
mean age of 11 ± 6 (SD) years. Inclusion criteria were
the diagnosis of CF by clinical symptoms and positive
sweat tests or disease-inducing mutations, forced expira-
tory volume in 1 second (FEV1) > 25% of predicted
value and being on stable concomitant therapy at least
2 weeks prior to the study. Among all 39 CF patients,
17 patients were colonized with P. aeruginosa and
19 patients with S. aureus. Twenty-five CF patients were
ΔF508 homozygous, nine were ΔF508 heterozygous car-
riers of the CFTR gene and five had other CFTR muta-
tions than ΔF508. The CF patients had moderate to
Table 1 Patient groups
Pneumonia Cystic fibrosis Asthma Controls
bacterial non-bacterial
N3 1 1 7 3 9 1 5 8
Age [yrs] 10 ± 5 12 ± 7 11 ± 6 10 ± 4 9 ± 4
Sex (m:f) 19/12 9/8 23/16 7/8 5/3
CRP (mg/l) 114 ± 64 53 ± 25 8 ± 3 12 ± 4 2 ± 1
WBC (10
9/l) 20 ± 8 11 ± 5 9 ± 4 10 ± 5 8 ± 2
Atopy 4/31 5/17 11/39 15/15 0/8
FEV1 (% pred) - - 95 ± 20 68 ± 12 -
FVC (% pred) - - 93 ± 19 73 ± 26 -
Bacteria detected 31 0 30/39 3/15 0/8
BALF cells
Viability (%) 76 ± 20 70 ± 14 76 ± 34 81 ± 26 85 ± 13
Recovery (%) 62 ± 24 52 ± 18 42 ± 17 56 ± 11 58 ± 18
Total cells (10
3/ml) 962 ± 303 712 ± 144 3240 ± 9380 240 ± 113 145 ± 23
Neutrophils (%) 38 ± 24 10 ± 13 63 ± 31 16 ± 23 2 ± 1
Macrophages (%) 55 ± 28 62 ± 34 33 ± 16 74 ± 21 87 ± 9
Lymphocytes (%) 12 ± 16 20 ± 11 5 ± 3 13 ± 14 5 ± 3
Eosinophils (%) 4 ± 2 2 ± 3 2 ± 1 5 ± 2 0 ± 0
Mast cells (%) 1 ± 1 1 ± 2 1 ± 1 2 ± 1 0 ± 1
Plasma cells (%) 4 ± 7 8 ± 5 3 ± 4 6 ± 4 2 ± 1
BALF cells analyzed by flow cytometry 15/31 8/17 9/39 13/15 8/8
results are expressed as means ± SD; m: male, f: female; WBC: white blood count; FEV1: Forced expiratory volume in 1 second (% of predicted); FVC: Forced vital
capacity (% of predicted); BALF: bronchoalveolar lavage fluid; CRP: C-reactive protein; WBC: white blood cell count; *Pathogens detected in any patients sample
at time of study (blood, BALF or sputum).
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Page 2 of 13severe disease severity, as defined by the activity and
physical examination criteria of the scoring system of
Shwachman and Kulczycki [13]. All CF patients were
clinically stable at least 2 months prior to the study, as
indicated by lack of self-reported change in symptoms
over the preceding 2 months, and none reported a
change in airway symptoms in the 2 months prior to
the study. BAL was performed for further diagnostic
clarification. The asthma group included 7 male and 8
female patients with a mean age of 10 ± 4 (SD) years.
Inclusion criteria were recurrent episodes of wheezing
and objective evidence of asthma as indicated by
b2-agonist-reversible airflow obstruction (≥12%
improvement in FEV1 % predicted), bronchial hyperre-
sponsiveness (exercise challenge) and ≥20% intraday
peak flow variability, positive skin prick testing (wheal
diameter of ≥3m mt oa tl e a s to n ec o m m o na l l e r g e n ) ,
elevated total serum IgE (>150 kU/ml; IgE-Elecsys,
Roche, Basel, Switzerland), and/or the presence of speci-
fic IgE (RAST class >2). The RAST was performed for
forty inhalation and food allergens (Sanofi Diagnostics
Pasteur, Inc, Chaska, MN). All asthma patients used
inhaled bronchodilators and nine asthma patients used
inhaled corticosteroids. Spirometry and flow volume
curves were performed according to the ATS guidelines
[14]. The clinical indication for BAL in pediatric asth-
matic patients was the severity and chronicity of the
asthmatic disease that prompted us to perform BAL for
a more extensive diagnostic workup, in order to exclude
non-asthmatic causes for the chronic pulmonary disease.
Eight age-matched control subjects without pulmonary
diseases were selected as the control group (5 male, 3
female; mean age: 9 ± SD 4 years) as described pre-
viously [15,16]. These subjects had no suspected or pro-
ven pulmonary disease and were free of respiratory tract
infections. The control subjects underwent minor surgi-
cal interventions and BAL was performed prior to the
surgical procedure for research purposes. This study
was approved by the institutional review board of the
LMU Children’s hospital. Written informed consent was
received from all patients or their parents.
Bronchial alveolar lavage
Bronchoscopy and BAL (4 × 1 ml of 0.9% NaCl per kg
body weight) were performed as described previously
[17]. The obtained BALF was filtered through two layers
of sterile gauze and was centrifuged at 200 g for 10 min-
utes. The cell pellet immediately underwent flow cyto-
metric analysis of mCD14 expression on alveolar
macrophages as described below.
BALF was divided into two samples: one for cytospin
preparation and sCD14 analysis and one for quantitative
bacterial culture. Cytospins were performed out of
native BALF. Differential cell counts were obtained from
cytospins stained with May-Gruenwald-Giemsa (Diff-
Quik; Baxter Diagnostic AG, Düdingen, Switzerland). At
least 600 cells were counted in each subject. Pathogens
in BALF were detected as described previously [18].
ELISA
sCD14 levels were measured in duplicates by a commer-
cially available, sandwich enzyme-linked immunosorbent
assay (ELISA) kit (Immunobiological Laboratories, Ham-
burg, Germany) according to the manufacturer’s instruc-
tions. We performed initial studies to test whether
processing of CF BAL affects sCD14 quantification.
These studies showed that filtration and centrifugation
of CF BAL had no significant effect on sCD14 levels.
The lower detection limit of the assay was 7 ng/ml.
Intra-assay variability was determined by evaluating 5
serum samples 10 times within the same assay run and
showed a coefficient of variation (CV) between 5% and
8%. Inter-assay variability was determined by measuring
5 serum samples in 5 consecutive assay runs and
showed a CV between 6% and 11%.
Flow cytometry
The following monoclonal anti-human antibodies were
used (all from BD Pharmingen, San Diego, CA, USA):
mouse IgM CD15 FITC, mouse IgG1 CD45 APC, mouse
IgG2a CD14-Cy5.5, mouse IgG2b CD68-PE, mouse IgM
FITC, mouse IgG1 APC, mouse IgG2a Cy5.5 and mouse
IgG2b PE. Peripheral blood cells and BALF cells were
analyzed by flow cytometry. Monocytes in peripheral
blood were detected according to their forward-/side-
scatter characteristics (FSC/SCC). Alveolar macrophages
in BALF were detected as described previously [19,20].
Alveolar macrophages were detected by positive expres-
sion for CD45, negative staining for CD15 and their
high expression of CD68. For antibody staining, cells
were incubated with the respective antibodies for 40
minutes and analyzed by flow cytometry (FACSCalibur,
Becton-Dickinson, Heidelberg, Germany). Isotype con-
trols were subtracted from the respective specific anti-
body expression and the results were reported as mean
fluorescence intensity (MFI). Calculations were per-
formed with Cell Quest analysis software (Becton-Dick-
inson, Heidelberg, Germany).
In vitro stimulation
PBMCs were isolated from human peripheral blood by
Ficoll-Hypaque (Amersham Pharmacia, Piscataway, NJ)
gradient centrifugation. Recombinant flagellin (Salmo-
nella typhimurium, TLR5 ligand), nonmethylated CpG-
oligonucleotides type A (5’ggGGGACGATCGTCgggggg
3’, stimulatory TLR9 ligand), peptidoglycan (PGN; from
Staphylococcus aureus, TLR2/NOD2 ligand), the syn-
thetic bacterial lipoprotein Pam3CysSerLys4 (Pam3CSK4,
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TLR2/6 ligand) and LPS from E. coli (TLR4 ligand)were
from Invivogen (San Diego, CA, USA). R848 (resiqui-
mod hydrochloride; a single-stranded RNA analog;
TLR7/8) was purchased from GL Synthesis (Worcester,
MA, USA). Polyinosine-polycytidylic acid (poly I:C) (a
double-stranded RNA analog; TLR3) was obtained from
Pharmacia (Uppsala, Sweden). Phorbol myristate acetate
(PMA) and phenylmethylsulfonyl fluoride (PMSF) were
from Sigma-Aldrich (St. Louis, MO, USA). All reagents,
buffers and media were free of LPS (<0.01 ng/ml) by
Limulus assay (Sigma-Aldrich).
Since it has been reported that LPS modulates sCD14
and mCD14 most significantly upon long-term incuba-
tion (>36 hours)[21], PBMCs (2 × 10
6) were stimulated
in RPMI medium for 1 hour or 40 hours with PMA
(10 ng/ml), fMLP (100 ng/ml) and of LPS (100 ng/ml),
Pam3CSK4 (1 μg/ml), PGN (1 μg/ml), poly I:C (50 μg/
ml), R848 (10 μg/ml), CpG-DNA (100 μg/ml), flagellin
(1 μg/ml) or zymosan (50 μg / m l )a t3 7 ° C .W h e r ei n d i -
cated, PBMCs (2 × 10
6) were pretreated for 1 hour with
the protease inhibitor PMSF (10 mM) and were then sti-
mulated for 40 hours at 37°C with RPMI, CpG-DNA
(100 μg/ml) or LPS (100 ng/ml).
Statistical analysis
Since the data distribution was non-parametric, results
are given as medians with ± interquartile ranges (IQRs)
or medians with ranges. Comparisons among all groups
were performed with the Kruskall-Wallis test and com-
parisons between two patient groups were performed
with the Mann-Whitney U test. Correlation analysis was
performed by calculating the two-tailed Spearman rank
correlation test [22]. Diagnostic value of the serological
markers for diagnosis of bacterial pneumonia and recei-
ver operator characteristics (ROC) curves were calcu-
lated using STATA® version 8.2 for Windows (STATA
Corporation, College Station, TX, USA). Cut-off levels
were set at the level that resulted in the highest diagnos-
tic accuracy, defined as correctly positive classified plus
correctly negative classified as percentage of all.
Results
Soluble CD14 is increased in pediatric pneumonia
Soluble CD14 levels were significantly increased in
serum of children with pneumonia (including patients
with bacterial and non-bacterial pneumonia; median:
11433 ng/ml; range: 5429-15460 ng/ml) compared to CF
(median: 4168; ng/ml; range: 2437-6061 ng/ml), asthma
(median: 2960; ng/ml; range: 2134-5588 ng/ml) and con-
trol (median: 2654; ng/ml; range: 2154-3764 ng/ml) sub-
jects with almost no overlap between pneumonia
patients and the other patient groups (Figure 1). Soluble
CD14 serum levels of children with CF or asthma did
not differ from sCD14 levels of control children. Similar
to sCD14 levels, mCD14 expression levels on peripheral
blood monocytes were increased in pneumonia patients
compared to CF, asthma and control children (Figure 2).
In BALF, sCD14 levels were also significantly
increased in children with pneumonia (median: 43 ng/
ml; range: 8-198 ng/ml) compared to CF (median: 13
ng/ml; range: 6-44 ng/ml), asthma (median: 25; pg/ml;
range: 12-45 pg/ml) and control (median: 19 pg/ml;
range: 7-32 pg/ml) subjects, but overlapped substantially
with levels of non-pneumonia patients (Figure 3). Solu-
ble CD14 levels in BALF of children with CF or asthma
did not differ from sCD14 levels of control children.
Similar to sCD14 levels, mCD14 expression levels on
BALF macrophages were increased in pneumonia
patients compared to CF, asthma and control children
(Figure 4).
Stratifying pneumonia patients in bacterial and non-
bacterial patients, children with bacterial pneumonia
had significantly higher levels of sCD14 in serum, but
not in BALF, compared to pneumonia patients without
detection of bacterial pathogens (Figure 5). Among chil-
dren with bacterial pneumonia, patients with detection
of Streptococcus pneumoniae had higher sCD14 levels
compared to other patients (data not shown). A positive
correlation between sCD14 and mCD14 levels was
found in BALF of pneumonia patients (r = 0.47, p <
0.05) and in peripheral blood of pneumonia (r = 0.52,
p < 0.01) and CF patients (r = 0.42, p < 0.05).
In children with pneumonia, sCD14 levels in BALF
correlated positively with sCD14 serum levels (r = 0.32,
p < 0.05), whereas in CF, asthma and control children
no correlation was found. A positive correlation between
sCD14 levels and WBC was found in pneumonia (r =
0.41, p < 0.05) and CF patients (r = 0.39, p < 0.05), but
not in asthmatics and control subjects.
Since our results indicated that sCD14 serum levels
are particularly increased in bacterial pneumonia, we
analyzed the usefulness of sCD14 serum levels to differ-
entiate bacterial pneumonia from CF, asthma and
healthy controls in comparison to the traditionally used
markers CRP and WBC. In this limited number of
patients, soluble CD14 serum levels tended towards a
higher sensitivity, specificity and diagnostic accuracy
compared to CRP and WBC in the diagnosis of bacterial
pneumonia (Table 2).
Two distinct cellular mechanisms facilitate sCD14 release
To recapitulate in vitro which factors may induce the
high levels of sCD14 in serum of bacterial pneumonia
patients in vivo, we incubated PBMCs in short-term
(1 hour) and long-term culture (40 hours) conditions at
37°C with PMA, fMLP and several purified TLR ligands
a n da n a l y z e ds C D 1 4a n dm C D 1 4l e v e l sa f t e rt h e
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Page 4 of 13Figure 1 Soluble CD14 levels in serum. Soluble CD14 levels were analyzed by ELISA in serum of children with pneumonia (n = 48), CF
(n = 39), asthma (n = 15) and control children without pulmonary diseases (n = 8). Horizontal bars represent medians.
Figure 2 Membrane CD14 expression in peripheral blood. Membrane CD14 expression levels were analyzed by flow cytometry in peripheral
blood of children with pneumonia (n = 48), CF (n = 39), asthma (n = 15) and control children without pulmonary diseases (n = 8).
Bars represent medians ± IQRs. MFI: mean fluorescence intensity.
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Page 5 of 13incubation period. After 1 hour, PMA and LPS induced
sCD14 production, whereas after 40 hours of incubation,
LPS and CpGs most strongly induced the release of
sCD14 levels in cell-culture supernatants compared to
medium treatment (Figure 6). A protease-dependent
shedding and a protease-independent release of sCD14
have been described previously [10]. The mechanism of
CpG-mediated sCD14 release was further investigated
by pretreating the cultured cells with the serine protease
inhibitor PMSF and further stimulation for 1 hour or
40 hours (Figure 7) with LPS or CpGs. Whereas LPS-
mediated sCD14 release was almost completely inhibited
at both incubation periods by PMSF pretreatment, the
effect of CpGs on sCD14 levels after 40 hours of incuba-
tion was protease-independent since PMSF did not inhi-
bit CpG-induced sCD14 release by PBMCs. After
40 hours of incubation, LPS and CpGs cooperated in
the induction of sCD14 levels and pretreatment with
PMSF partially prevented the LPS and CpG mediated
sCD14 production by PBMCs. PMSF alone had no effect
on sCD14 production by PBMCs. Whereas PMA and
LPS decreased mCD14 expression on PBMCs after 1
hour of incubation, 40 hours of incubation with LPS
increased mCD14 expression (Figure 8). No effect of
CpG treatment on mCD14 expression was found after 1
hour or 40 hours of incubation.
Discussion
This study characterizes for the first time the expres-
sion, regulation, localization and clinical significance of
soluble and membrane CD14 receptors in pediatric
inflammatory lung diseases. sCD14 serum levels were
specifically increased in serum of children with pneumo-
nia compared to CF, asthma and control subjects. In
order to clarify which factors induce sCD14 production
in bacterial pneumonia, we found that the TLR ligands
LPS and CpGs induce sCD14 production via two dis-
tinct mechanisms.
Martin et al. examined sCD14 levels in BALF of adult
patients with pneumonia and found increased levels of
50 ng/ml compared to ARDS and control subjects with
a considerable overlap between ARDS and pneumonia
patients [11,23]. Since no serum was available in these
pneumonia patients, the sCD14 serum levels and their
diagnostic potential remained unknown. In further stu-
dies, high sCD14 serum levels were associated with
mortality in adult patients with Gram-negative [24] and
Gram-positive sepsis [25]. CRP is commonly used to
identify bacterial pneumonia in children and has been
found to have a higher sensitivity and specificity for
community-acquired pneumonia compared to WBC and
ESR, especially at levels >60 mg/l [26-30]. Nevertheless,
especially in children with pneumonia, the analysis of
Figure 3 Soluble CD14 levels in BALF. Soluble CD14 levels were analyzed by ELISA in BALF of children with pneumonia (n = 48), CF (n = 39),
asthma (n = 15) and control children without pulmonary diseases (n = 8). Horizontal bars represent medians.
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Page 6 of 13CRP has been discussed to yield unsatisfactory results
[31]. In our study, limited by the small number of
patients, CRP levels of >60 mg/l were present in 20 of
all 32 (= 63%) children with bacterial pneumonia and
had a high diagnostic accuracy of 93.6% for diagnosis of
pneumonia. sCD14 levels in serum reached a diagnostic
accuracy of 97.9%. This diagnostic accuracy was reached
for two different cut-off levels of sCD14 in serum (5429
and 8444 ng/ml). However, increased sCD14 serum
levels were not to be specific for bacterial pneumonia as
sCD14 levels were also elevated in patients with non-
bacterial pneumonia with a substantial overlap among
patient groups. More clinical studies including higher
numbers of children with pneumonia and comparing
sCD14 with other putative serum biomarkers are needed
to evaluate the potential role of sCD14 as biomarker for
pneumonia and to define the best cut-off value for
sCD14 serum levels in pediatric pneumonia.
The question arised which cells produce sCD14 and
why sCD14 levels were clearly higher in serum despite
pneumonia takes place primarily in the pulmonary com-
partment. To elucidate which factors may induce the
release of sCD14 in patients with bacterial pneumonia,
we stimulated PBMCs with TLR ligands in vitro, resem-
bling the human situation of children with pneumonia,
and quantified the resulting sCD14 production in PBMC
supernatants. Among viral and bacterial TLR ligands
tested, only bacterial LPS and CpG induced sCD14 pro-
duction. Whereas LPS triggered sCD14 release after
1h o u r ,t h ee f f e c to fC p G sb ecame obvious after long-
term incubation. Two mechanisms of sCD14 production
have been identified, a protease-dependent shedding
from the cell surface and a protease-independent release
of sCD14 before addition of the glycosyl phosphatidylino-
sitol anchor [10]. Interestingly, the protease inhibitor
PMSF had no effect on CpG-mediated sCD14 release.
Therefore, we speculate that CpG does not induce CD14
shedding but specifically induces sCD14 release by
PBMCs via a protease-independent cellular secretion
mechanism as found by Bufler et al. [10]. In line with the
stimulatory effect of LPS and CpG on sCD14 release by
PBMCs, we speculate that sCD14 levels in patients with
pneumonia might be mainly induced via the TLR4 and
TLR9 ligands LPS and CpGs, respectively. The intracellu-
lar signalling pathway that triggers sCD14 elaboration
upon CpG stimulation remains to be established.
Figure 4 Membrane CD14 expression in BALF. Membrane CD14 expression levels were analyzed by flow cytometry in BALF of children with
pneumonia (n = 48), CF (n = 39), asthma (n = 15) and control children without pulmonary diseases (n = 8). Bars represent medians ± IQRs.
MFI: mean fluorescence intensity.
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macrophages in BALF of children with pneumonia, but
decreased mCD14 expression on alveolar macrophages
of patients with CF compared to controls. Alexis et al
demonstrated that neutrophil elastase reduced CD14
expression on alveolar phagocytes in vitro,w h i c hm i g h t
represent the underlying cause for the low mCD14
expression on CF alveolar macrophages [32,33]. Two
previous studies demonstrat e dt h a ts h o r t - t e r mi n c u b a -
tion with LPS decreased mCD14, whereas long-term
LPS treatment resulted in increased mCD14 expression
on monocytes [21] and alveolar macrophages [34]. Our
findings indicate that 40 h incubation with LPS and
CpG induced sCD14 secretion and increased mCD14
expression of PBMCs. The LPS-induced increase of
mCD14 expression might explain the high mCD14
expression found on PBMCs and alveolar macrophages
from patients with pneumonia compared to CF, asthma
and control subjects. In patients with arthropathies,
sCD14 levels in serum correlated positively with CRP
levels and sCD14 was therefore characterized as an
acute-phase protein, produced mainly by hepatocytes
[35]. In contrast, in children with pneumonia in our
study we found no association between sCD14 levels
and CRP, but instead a positive correlation with WBC,
suggesting that leukocytes may represent a major source
of sCD14 in serum of pneumonia patients.
Given the heterogeneous pneumonia patient cohort
including patients with malignancies (especially ALL),
primary immunodeficiencies (especially chronic granulo-
matous disease, CGD), chronic bronchitis and recurring
pneumonia, the finding that sCD14 serum levels were
significantly increased in the presence of pneumonia
regardless of the diverse underlying pathology, suggests
that sCD14 serum levels primarily reflect the pulmonary
inflammation process independent of systemic disease
conditions.
Nevertheless, several questions on the diagnostic value
of sCD14 serum levels in childhood pneumonia remain
open: (i) what is the longitudinal course of sCD14
Figure 5 Soluble CD14 levels and bacterial pneumonia.B A L F
(A) and soluble (B) sCD14 levels are shown for pneumonia children
with (+, n = 31) or without (-, n = 17) bacterial pathogens detected.
Comparisons among all groups were performed with the Kruskall-
Wallis test and comparisons between two patient groups were
performed with the Mann-Whitney U test. Horizontal bars represent
medians.
Table 2 The value of sCD14 in serum and BALF compared
to CRP and WBC for diagnosing bacterial pneumonia
in children.
sCD14
serum
CRP WBC sCD14
BALF
Sensitivity
1 [%] 93.6 80.7 64.5 41.9
Specificity
2 [%] 100 100 96.8 96.8
Diagnostic accuracy
3 [%] 97.9
4 93.6 86.0 78.5
Area under the ROC
curve [%]
99.8 93.1 87.9 69.0
Cut-off value 8444 ng/ml 30 mg/l 14.0 × 10
9 55 ng/ml
1 Sensitivity is defined as the probability that a patient with pneumonia
shows elevated levels of the respective marker at the specific cut-off level.
2 Specificity is defined as the probability that a patient without pneumonia
shows levels of the respective marker below the specific cut-off level.
3 Diagnostic accuracy is defined as the number of correctly positive
categorized plus the number of correctly negative categorized as percentage
of all.
4 The same diagnostic accuracy (97.9%) was reached for sCD 14 in serum at a
cut-off value of 5429 ng/ml resulting in a sensitivity of 100% and a specificity
of 96.8%.
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Page 8 of 13Figure 6 In vitro stimulation of PBMCs. sCD14 levels in cell-culture supernatants were quantified in duplicates by ELISA. * p < 0.05 vs medium
treatment. PBMCs (2 × 10
6) in RPMI medium were stimulated with PMA (10 ng/ml), fMLP (100 ng/ml) or the TLR ligands CpG-DNA (100 μg/ml),
zymosan (50 μg/ml), PGN (1 μg/ml), Pam3CSK4 (1 μg/ml), flagellin (1 μg/ml) or LPS (100 ng/ml) for 1 hour (A) or 40 hours (B) at 37°C.
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Page 9 of 13Figure 7 Mechanisms of sCD14 release. PBMCs were preincubated for 1 hour with the serine protease inhibitor PMSF (10 mM) and were then
stimulated for 1 hour (C) or 40 hours (D) at 37°C with RPMI, CpG-DNA (100 μg/ml) or LPS (100 ng/ml).
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Page 10 of 13Figure 8 Mechanisms of sCD14 release. After stimulation of PBMCs (2 × 10
6) in RPMI medium with PMA (10 ng/ml), fMLP (100 ng/ml) or the
TLR ligands CpG-DNA (100 μg/ml), zymosan (50 μg/ml), PGN (1 μg/ml), Pam3CSK4 (1 μg/ml), flagellin (1 μg/ml) or LPS (100 ng/ml) for 1 hour
(E) or 40 hours (F) at 37°C, mCD14 expression levels on PBMCs were quantified by flow cytometry. MFI: mean fluorescence intensity.
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Page 11 of 13serum levels in children with pneumonia? (ii) is there a
predictive value of sCD14 levels in serum as prognostic
marker for the occurrence of pneumonia in childhood?
(iii) Are sCD14 serum levels increased prior to the full
clinical manifestation of pneumonia or are increased
sCD14 serum levels the consequence of an already exist-
ing pneumonia? These questions necessitate prospective
studies in large patient cohorts.
Surprisingly, CF patients who are chronically colo-
nized with bacterial infections had comparable sCD14
serum levels as healthy controls. We speculate that
there are three possible causes for this observation: (i)
sCD14 has been described as an acute phase protein.
Since CF is a chronic disease, sCD14 serum levels might
be exclusively increased in acute bacterial infections;
(ii) elastase, present at large amounts in CF airways, has
been shown to cleave mCD14 from monocytes [36] and
alveolar macrophages [32]. Thus, elastase in CF lungs
could decrease mCD14 and thereby reduce the mCD14
amount to be cleaved by LPS and shedded into the air-
way environment; (iii) the intrinsic genetic mutation in
t h eC F T Rg e n em i g h ti n f l u e n c et h ee x p r e s s i o na n do r
release of sCD14, a hypothesis to be tested in the future.
Conclusions
We demonstrate that sCD14 levels were increased in
serum of children with pneumonia compared to CF,
asthma and control subjects with the highest levels
found in children with bacterial pneumonia. Functional
studies revealed two distinct cellular mechanisms med-
iating the release of sCD14. Soluble CD14 levels may
serve as a novel biomarker marker for bacterial pneu-
monia in children.
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